Neuroimaging of the Effects of Concerta in the Treatment of ADHD

Completed · Phase 4 · Has a placebo group

Conditions studied: Attention Deficit Disorder With Hyperactivity

In brief

A number of brain regions have been down to be altered in both structure and function in patients with ADHD, including prefrontal cortex, anterior cingulate, caudate and cerebellum. Patients with ADHD often show reduced levels of activity in the frontal and cingulate regions of brain while performing measures of inhibitory control during functional magnetic resonance imaging (fMRI). While stimulant medications robustly improve the clinical symptoms of ADHD, there are only a small number of studies examining the effects of these commonly prescribed medications on brain activity. We propose to obtain fMRI in patients with ADHD on placebo and on their individualized dose of OROS methylphenidate (Concerta). Our hypothesis is that Concerta will increase the activity of the brain in the frontal, cingulate and amygdala of the brain and that these brain changes will be associated with clinical improvement of symptoms.

Key facts

Study ID
NCT00778310
Run by
The University of Texas Health Science Center at San Antonio
People needed
76
Starts
2008-11-01
Expected to finish
2010-12-01
Last updated by the study team
2012-07-13

Who can join

Age: 9 and older, up to 25. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.